ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0607

Cadherin 6 Regulates Rheumatoid Arthritis Fibroblasts-Like Synoviocyte Aggressiveness
Abstract Number: 1819

Calcium Pyrophosphate Deposition Disease Is Associated with an Increased Prevalence of Nephrolithiasis
Abstract Number: 2184

CaMK4 Controls the Humoral Response via the T Follicular Helper Compartment and Regulates Autoimmunity
Abstract Number: 0477

Can Beta-blockers Prevent Aortic Dilation in Patients with Giant Cell Arteritis and Large Vessel Vasculitis?
Abstract Number: 1238

Can Thermal Imaging Help Clarify Joint Inflammation at Clinically Quiescent Metacarpophalangeal Joints in Patients with Rheumatoid Arthritis?
Abstract Number: 0767

Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO) – A Retrospective Chart Review Study of Adults with Inflammatory Arthritis Associated with Cancer Immunotherapies
Abstract Number: 0813

Canakinumab in Patients with Tumor Necrosis Factor Receptor-associated Periodic Syndrome (TRAPS) – Long-term Efficacy and Safety Data from a RELIANCE Registry Interim Analysis
Abstract Number: 1834

Canakinumab Treatment in Familial Mediterranean Fever Patients with Colchicine Resistance: A Single-center Study
Abstract Number: 1752

Cancer Risk in Patients with Rheumatic Diseases Exposed to Different Biologic and Targeted Synthetic DMARDs in Real World Clinical Practice: Data from BIOBADASER
Abstract Number: 0267

Cancer Risk with Biologic and Targeted Synthetic DMARDs in Patients with Rheumatic Diseases and Previous Malignancy: Results from the BIOBADASER Register
Abstract Number: 0002

Cancer Screening Recommendations for Patients with Idiopathic Inflammatory Myopathy
Abstract Number: 1066

Capillaroscopic Findings in Autoimmune Connective Tissue Diseases: Results from 20 Years of Experience in a Training Referral Center
Abstract Number: 0069

Capturing Clinical Reasoning in Real Time Reveals Low Rate of Serious Adverse Reactions Requiring B/tsDMARD Discontinuation in Inflammatory Joint Disease: An Analysis of the OPAL Real-World Dataset
Abstract Number: 1651

CAR T Cell Treatment of Refractory Systemic Lupus Erythematosus
Abstract Number: 0539

Cardiac Complications, Thrombosis, Infections and All-cause Mortality Among Patients with End-Stage Kidney Disease Due to Lupus Nephritis in the USRDS 2006-2013 According to SLE Medication Use

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].